Is NCT03186495 results overdue?

Yes — results are overdue. Primary completion was 2018-05-17; the FDAAA-801 reporting deadline (2019-05-17) passed 2638 days ago and no results are posted on ClinicalTrials.gov.

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

NCT ID	NCT03186495 ↗
Sponsor	Novo Nordisk A/S (INDUSTRY)
Public issuer	NOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
Phase	PHASE1
Status	COMPLETED
Primary completion	2018-05-17 (ACTUAL)
Reporting deadline	2019-05-17 (completion + 365d)
Days overdue	2638
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `3ffe1ab5a4277850…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03186495. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.